literature

HIV mutation literature information.

Phase 2 Open-Label Study of Long-Term Safety, Tolerability, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive Adolescents Living with HIV-1.

PMID: 34871089 2022 Antimicrobial agents and chemotherapy

Method: Patients with previously documented HIV-2 infection, with active AIDS, and with documented genotypic evidence of >=1 NNRTI resistance-associated mutation (RAM) from a predefined list of the following NNRTI RAMs at screening were excluded: A98G, L100I, K101E, K101P, K101Q, K103H, K103N, K103S, K103T, V106A, V106M, V108I, E138A, E138G,

HIV-1 drug resistance among individuals who seroconverted in the ASPIRE dapivirine ring trial.

PMID: 34762770 2021 Journal of the International AIDS Society

Table: K103H/T

Prevalence of HIV-1 Drug-Resistance Genotypes Among Unique Recombinant Forms from Yunnan Province, China in 2016-2017.

PMID: 31914782 2020 AIDS research and human retroviruses

Abstract: Mutations such as M184V/I (35.4%) in NRTIs and K103N/R/S/T (25.4%), V179D/E/T/Y (18.9%), G190A/E/R/S (13.8%), and Y181C (9.2%) in NNRTIs were common among the HIV-1 URF strains relative to other mutations.

Trends in HIV-1 Drug Resistance Mutations from a U.S. Reference Laboratory from 2006 to 2017.

PMID: 31169022 2019 AIDS research and human retroviruses

Abstract: K103N/S/T declined from 42.5% in 2012 to 36.4% in 2017.

A decade of viral mutations and associated drug resistance in a population of HIV-1+ Puerto Ricans: 2002-2011.

PMID: 28493944 2017 PloS one

Result: The RT mutations with the highest average frequencies were M184V (47.9%), K103N (42.6%) and M41L (34.2%) (Figs 2 and 5); the three least common RT mutations over the 10-year period were K103T, Y188C and P236L (S1 Table).

HIV-1 drug-resistant mutations and related risk factors among HIV-1-positive individuals experiencing treatment failure in Hebei Province, China.

PMID: 28114955 2017 AIDS research and therapy

Table: K103T

Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study.

PMID: 27120449 2016 PloS one

Method: RT-RAMs were identified and analyzed by using the Stanford Drug Resistance Database for V90I, A98G, L100I/V, K101E/P/Q/H/N, K103N/S/T/Q/E/H/R, V106A/M/I, V108I, E138A/K/Q/G/R, V179D/E/T/F/L, Y181C/I/V/S/F/G, M184I, Y188C/H/L/F, G190A/S/E/Q/C/V/T, H221Y,

Mechanism of allosteric inhibition of HIV-1 reverse transcriptase revealed by single-molecule and ensemble fluorescence.

PMID: 25232099 2014 Nucleic acids research

Figure: (J) FRET histograms for K103NT RT-T/P and RT-T/P-dNTP complexes in the absence and presence of EFV (N = 178, 138, 156 and 150 individual traces, respectively).

Concordance between allele-specific PCR and ultra-deep pyrosequencing for the detection of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.

PMID: 25034127 2014 Journal of virological methods

Method: Unusual polymorphisms at the 103 position (K103R and K103T) were shown not to compromise the K103N assay, but polymorphisms at the 181 position (Y181F/S) produced false positive results so the one sample with this polymorphism was excluded from analysis.

Result: Sample 11 had an unusual polymorphism (K103T) which alternatively may have contributed to a false positive in the AS-PCR assay.

Identification of drug resistant mutations in HIV-1 CRF07_BC variants selected by nevirapine in vitro.

PMID: 22984494 2012 PloS one

Discussion: Thus far, about 32 NVP-resistance associated mutations in 17 positions, including 15 major NVP-resistant mutations at 5 positions (K103NST, V106AM, Y181CIV, Y188LHC, G190ASEQ), have been summarized in HIV drug resistance database of Stanford University.

Browser Board

Co-occurred Entities

Filtrator